LC–MS-based serum metabolomics reveals distinct metabolic signatures in patients with intracerebral Hemorrhage
-
By
-
Wei Zheng
-
Wei Wang
-
Xiaohui Lu
-
July 2, 2026
-
Clinical Scorecard: Serum Metabolic Profiles Identified in Intracerebral Hemorrhage Patients Through LC–MS Analysis
At a Glance
| Category | Detail |
|---|
| Condition | Intracerebral Hemorrhage (ICH) |
| Key Mechanisms | Metabolic alterations in serum profiles associated with ICH pathogenesis. |
| Target Population | Patients aged 18–65 with confirmed ICH. |
| Care Setting | Clinical research setting for metabolic analysis. |
Key Highlights
- 3,178 metabolites identified in serum of ICH patients.
- Benzene derivatives and organic acids were the most abundant metabolite classes.
- Significant diagnostic performance for metabolites like Dibutyl phthalate (AUC = 0.980).
- Metabolomic analysis provides insights into ICH pathogenesis.
- Potential biomarkers identified for early diagnosis and risk assessment.
Guideline-Based Recommendations
Diagnosis
- Utilize serum metabolite profiling for potential early diagnosis of ICH.
Management
- Consider metabolic biomarkers for targeted intervention in ICH.
Monitoring & Follow-up
- Dynamic changes in metabolite levels may assess disease progression.
Risks
- ICH carries high mortality and disability rates; early detection is crucial.
Patient & Prescribing Data
Patients with confirmed ICH aged 18–65.
Metabolomic profiles may guide personalized treatment strategies.
Clinical Best Practices
- Incorporate metabolomic analysis in the assessment of ICH.
- Use established biomarkers alongside conventional imaging for comprehensive evaluation.
Related Resources & Content
